Evidence mapPaperPMID 35920161Full record

Trial reportObesity (Silver Spring, Md.)2022

Association of cognition with leptin and vascular endothelial growth factor in individuals with type 2 diabetes mellitus.

Mark A Espeland, Joni K Evans, Owen Carmichael, Jose A Luchsinger, Santica M Marcovina, Rebecca Neiberg, Karen C Johnson, Steven E Kahn, Kathleen M Hayden, Action for Health in Diabetes (Look AHEAD) MIND Ancillary Study Group

Open access · hybridAbstract readClinical Trial
In one paragraph

Trial report in Obesity (Silver Spring, Md.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Does lifestyle intervention lower clinically significant cognitive impairment risk?Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Trial
  2. Trial
  3. Trial
  4. Identification of serum biomarkers associated with microvascular functions in a long-term high-fat diet-induced obesity rat model.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Mark A EspelandSticht Center for Healthy Aging and Alzheimer's Prevention, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.ORCID 0000-0002-3711-1949
Joni K EvansDepartment of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Owen CarmichaelPennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
Jose A LuchsingerDepartment of Medicine, Columbia University Medical Center, New York, New York, USA.
Santica M MarcovinaMedpace Reference Laboratories, Cincinnati, Ohio, USA.
Rebecca NeibergDepartment of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Karen C JohnsonDepartment of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.ORCID 0000-0002-3493-4077
Steven E KahnDivision of Metabolism, Endocrinology, and Nutrition, VA Puget Sound Health Care System and University of Washington, Seattle, WA, USA.
Kathleen M HaydenDepartment of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.ORCID 0000-0002-7745-3513
Action for Health in Diabetes (Look AHEAD) MIND Ancillary Study Group
Wake Forest University · USColumbia University Irving Medical Center · USMedpace (United States) · USPennington Biomedical Research Center · USUniversity of Tennessee Health Science Center · USUniversity of Washington · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
Look AHEAD: Action for Health in DiabetesU01DK057136 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ESPELAND, MARK ANDREW, WAGENKNECHT, LYNNE E · 1999 to 2020
$54.9M
Wake Forest University School of Medicine Alzheimer's Disease Research CenterP30AG072947 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SUZANNE CRAFT · 2021 to 2026
$24.3M
Wake Forest Alzheimer's Disease Core CenterP30AG049638 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BATEMAN, JAMES R., CRAFT, SUZANNE · 2016 to 2020
$12.2M
Long-term impact of random assignment to intensive lifestyle intervention on Alzheimers disease and related dementias: The Action for Health in Diabetes ADRD Study (Look AHEAD-MIND)R01AG058571 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ESPELAND, MARK ANDREW, HAYDEN, KATHLEEN M · 2018 to 2021
$8.4M
New York Regional Center for Diabetes Translation Research - Translational Intervention Methodology CoreP30DK111022 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI JEFFREY GONZALEZ · 2016 to 2026
$7.8M
LA-Aging Diversity SupplementU01AG073697 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ESPELAND, MARK ANDREW, WAGENKNECHT, LYNNE E · 2021 to 2025
$7.1M
Intentional weight reduction and physical and cognitive functionR01AG033087 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI KRITCHEVSKY, STEPHEN B. · 2009 to 2013
$4.0M
Action for Health in Diabetes Brain Magnetic Resonance Imaging Ancillary StudyR01DK092237 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ESPELAND, MARK ANDREW · 2011 to 2014
$3.6M
Midcareer Award for Research in Dementia Risk Factors and PreventionK24AG045334 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Jose Alejandro Luchsinger · 2016 to 2026
$1.5M
NIA NIH HHS K24 AG045334NIA NIH HHS P30 AG049638NIA NIH HHS P30 AG072947NIA NIH HHS R01 AG033087NIA NIH HHS R01 AG058571NIA NIH HHS U01 AG073697NIDDK NIH HHS P30 DK111022NIDDK NIH HHS R01 DK092237NIDDK NIH HHS U01 DK057136NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

objectiveThe 10-year intensive lifestyle intervention (ILI) of the Look AHEAD study left a legacy of relative deficits in cognitive function among participants who entered the clinical trial with obesity or a history of cardiovascular disease. We hypothesized that altered levels of two weight-sensitive proangiogenic cytokines, leptin and vascular endothelial growth factor (VEGF), accounted for this concerning finding.

methodsSerum leptin and VEGF concentrations were determined in 1,279 Look AHEAD participants at baseline, proximal to cessation of the interventions (Epoch 1), and an average of 4 years later (Epoch 2). Up to four standardized assessments of attention, executive function, and memory were collected during follow-up. Mixed effects models were used to assess relative differences in leptin and VEGF concentrations between intervention groups and whether these accounted for changes in cognitive composite scores.

resultsILI and diabetes support and education differences in VEGF, but not leptin, concentrations varied depending on baseline history of cardiovascular disease and obesity, but neither leptin nor VEGF concentrations accounted for the relative decrements in cognitive function in participants assigned to ILI.

conclusionsAlterations in two weight-sensitive proangiogenic cytokines did not account for the long-term adverse effects of ILI on cognitive function among adults with diabetes and either obesity or cardiovascular disease.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2CognitionCytokinesHumansLife StyleObesityOverweightVascular Endothelial Growth Factor AWeight LossCytokinesVascular Endothelial Growth Factor A

Identifiers

PMID35920161
PMCPMC9420754
OpenAlexW4289711365

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.